Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats
| Autor: | Regina Demlová, Katerina Horska, Michal Karpisek, Tomáš Kašpárek, Eva Drazanova, Hana Kotolová, Jana Ruda-Kucerova |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Leptin
Male 0301 basic medicine medicine.medical_specialty Offspring Aripiprazole Administration Oral Adipokine Pharmacology Energy homeostasis Random Allocation 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Glucagon-Like Peptide 1 Internal medicine medicine Animals Rats Wistar Metabolic Syndrome medicine.diagnostic_test business.industry Body Weight medicine.disease Ghrelin 3. Good health Disease Models Animal Poly I-C 030104 developmental biology Endocrinology Schizophrenia Cytokines Metabolic syndrome Lipid profile business 030217 neurology & neurosurgery Antipsychotic Agents Hormone medicine.drug |
| Zdroj: | Neuropharmacology. 123:148-158 |
| ISSN: | 0028-3908 |
| Popis: | Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Aripiprazole is considered to represent an antipsychotic drug with low risk of metabolic syndrome development. The aim of this study was to evaluate metabolic phenotype of neurodevelopmental polyI:C rat model and assess metabolic effects of chronic aripiprazole treatment with regard to complex neuroendocrine regulations of energy homeostasis. Polyinosinic:polycytidylic acid (polyI:C) was administered subcutaneously at a dose of 8 mg/kg in 10 ml on gestational day 15 to female Wistar rats. For this study 20 polyI:C and 20 control adult male offspring were used, randomly divided into 2 groups per 10 animals for chronic aripiprazole treatment and vehicle. Aripiprazole (5 mg/kg, dissolved tablets, ABILIFY®) was administered once daily via oral gavage for a month. Altered lipid profile in polyI:C model was observed and a trend towards different dynamics of weight gain in polyI:C rats was noted in the absence of significant antipsychotic treatment effect. PolyI:C model was not associated with changes in other parameters i.e. adipokines, gastrointestinal hormones and cytokines levels. Aripiprazole did not influence body weight but it induced alterations in neurohumoral regulations. Leptin and GLP-1 serum levels were significantly reduced, while ghrelin level was elevated. Furthermore aripiprazole decreased serum levels of pro-inflammatory cytokines. Our data indicate dysregulation of adipokines and gastrointestinal hormones present after chronic treatment with aripiprazole which is considered metabolically neutral in the polyI:C model of schizophrenia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect